PE20240797A1 - Composiciones farmaceuticas de un anticuerpo contra pd-1 y uso de las mismas - Google Patents

Composiciones farmaceuticas de un anticuerpo contra pd-1 y uso de las mismas

Info

Publication number
PE20240797A1
PE20240797A1 PE2024000052A PE2024000052A PE20240797A1 PE 20240797 A1 PE20240797 A1 PE 20240797A1 PE 2024000052 A PE2024000052 A PE 2024000052A PE 2024000052 A PE2024000052 A PE 2024000052A PE 20240797 A1 PE20240797 A1 PE 20240797A1
Authority
PE
Peru
Prior art keywords
antibody against
pharmaceutical compositions
approximately
pharmaceutical composition
cancer
Prior art date
Application number
PE2024000052A
Other languages
English (en)
Spanish (es)
Inventor
Krishnan Sampathkumar
Yan Zhou
Stephen James Burke
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of PE20240797A1 publication Critical patent/PE20240797A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PE2024000052A 2021-07-09 2022-06-22 Composiciones farmaceuticas de un anticuerpo contra pd-1 y uso de las mismas PE20240797A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163220006P 2021-07-09 2021-07-09
PCT/US2022/034493 WO2023283049A1 (en) 2021-07-09 2022-06-22 Pharmaceutical compositions of a pd-1 antibody and use of the same

Publications (1)

Publication Number Publication Date
PE20240797A1 true PE20240797A1 (es) 2024-04-18

Family

ID=82608118

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024000052A PE20240797A1 (es) 2021-07-09 2022-06-22 Composiciones farmaceuticas de un anticuerpo contra pd-1 y uso de las mismas

Country Status (17)

Country Link
US (2) US12364756B2 (cg-RX-API-DMAC10.html)
EP (1) EP4366692A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024525566A (cg-RX-API-DMAC10.html)
KR (1) KR20240035533A (cg-RX-API-DMAC10.html)
CN (1) CN118215465A (cg-RX-API-DMAC10.html)
AR (1) AR126404A1 (cg-RX-API-DMAC10.html)
AU (1) AU2022307332A1 (cg-RX-API-DMAC10.html)
CA (1) CA3224640A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024000077A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024000198A2 (cg-RX-API-DMAC10.html)
CR (1) CR20240065A (cg-RX-API-DMAC10.html)
EC (1) ECSP24008791A (cg-RX-API-DMAC10.html)
IL (1) IL309985A (cg-RX-API-DMAC10.html)
MX (1) MX2024000268A (cg-RX-API-DMAC10.html)
PE (1) PE20240797A1 (cg-RX-API-DMAC10.html)
TW (1) TW202308694A (cg-RX-API-DMAC10.html)
WO (1) WO2023283049A1 (cg-RX-API-DMAC10.html)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2476934C (en) * 2002-02-27 2009-06-16 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
PE20231958A1 (es) * 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3705134A4 (en) * 2017-11-02 2021-07-28 Nanjing Shunxin Pharmaceutical Co., Ltd. PHARMACEUTICAL COMPOSITION CONTAINING A HUMANIZED MONOCLONAL ANTIBODY ANTI-PD-L1
IL277095B2 (en) * 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
CN110404066B (zh) * 2018-04-28 2022-06-17 齐鲁制药有限公司 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途
WO2021022172A1 (en) 2019-08-01 2021-02-04 Incyte Corporation A dosing regimen for an ido inhibitor
CN114206386A (zh) 2019-08-05 2022-03-18 小野药品工业株式会社 免疫检查点抑制剂的有效性判定生物标记

Also Published As

Publication number Publication date
KR20240035533A (ko) 2024-03-15
JP2024525566A (ja) 2024-07-12
CA3224640A1 (en) 2023-01-12
US20230025464A1 (en) 2023-01-26
AR126404A1 (es) 2023-10-11
EP4366692A1 (en) 2024-05-15
CR20240065A (es) 2024-04-08
TW202308694A (zh) 2023-03-01
AU2022307332A1 (en) 2024-01-18
US20250345422A1 (en) 2025-11-13
WO2023283049A1 (en) 2023-01-12
IL309985A (en) 2024-03-01
ECSP24008791A (es) 2024-03-01
MX2024000268A (es) 2024-01-31
US12364756B2 (en) 2025-07-22
CN118215465A (zh) 2024-06-18
CO2024000198A2 (es) 2024-02-05
CL2024000077A1 (es) 2024-08-23

Similar Documents

Publication Publication Date Title
AR124140A2 (es) Formulaciones de anticuerpos
DOP2022000115A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio
PE20131324A1 (es) Formulacion subcutanea de anticuerpo anti-her2
PE20190469A1 (es) Formulaciones, kits y metodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados
AR063201A1 (es) Composiciones farmaceuticas de ropinirol y metodos de uso de las mismas
CO2022017622A2 (es) Inhibidores de quinasa nek7
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
IN2015MU00865A (cg-RX-API-DMAC10.html)
AR054805A1 (es) Composiciones topicas para el tratamiento de la piel
MX2017010131A (es) Composiciones farmaceuticas para terapia combinada.
AR081364A1 (es) Composiciones farmaceuticas de pazopanib y metodos para su elaboracion
BR112022001897A2 (pt) Composições de higiene pessoal
MX2024013019A (es) Compuestos de heteroarilo para el tratamiento del dolor
CO2023014204A2 (es) Inhibidores de la cinasa relacionada con el gen nunca en mitosis a 7 (nek7)
BR112023023463A2 (pt) Inibidores da interação menin-mll
PE20220376A1 (es) Compuestos triciclicos y su uso
CL2024000560A1 (es) Inhibidores de indolina de kif18a
CO2021010493A2 (es) Compuestos de halo-alilamina y uso de los mismos
CO2023004540A2 (es) Formas farmacéuticas sólidas de bacterias
CO2025013357A2 (es) Conjugados de ligando-fármaco citotóxico y usos farmacéuticos de estos
EA202191345A1 (ru) Стабильный состав глюкокортикоидов
CL2025002366A1 (es) Compuesto que contiene trifluorometilsulfonilo.
ECSP24028472A (es) Administración facilitada de formulaciones concentradas de anticuerpos mediante el uso de hialuronidasa
MX2021014103A (es) Compuestos de briostatina para mejorar la inmunoterapia.
CO6280488A2 (es) Combinacion farmaceutica